From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).

Journal Article (Journal Article)

Our understanding of the molecular mechanisms underlying the pharmacological actions of estrogen receptor (ER) ligands has evolved considerably in recent years. Much of this knowledge has come from a detailed dissection of the mechanism(s) of action of the Selective Estrogen Receptor Modulators (SERMs) tamoxifen and raloxifene, drugs whose estrogen receptor (ER) agonist/antagonist properties are influenced by the cell context in which they operate. These studies have revealed that notwithstanding differences in drug pharmacokinetics, the activity of an ER ligand is determined primarily by (a) the impact that a given ligand has on the receptor conformation and (b) the ability of structurally distinct ER-ligand complexes to interact with functionally distinct coregulators. Exploitation of the established relationships between ER structure and activity has led to the development of improved SERMs with more favorable therapeutic properties and of tissue-selective estrogen complexes, drugs in which a SERM and an ER agonist are combined to yield a blended activity that results in distinct clinical profiles. Remarkably, endogenous ligands that exhibit SERM activity have also been identified. One of these ligands, 27-hydroxycholesterol (27HC), has been shown to manifest ER-dependent pathological activities in the cardiovascular system, bone and mammary gland. Whereas the physiological activity of 27HC remains to be determined, its discovery highlights how cells have adopted mechanisms to allow the same receptor ligand complex to manifest different activities in different cells, and also how these processes can be exploited for new drug development.

Full Text

Duke Authors

Cited Authors

  • Wardell, SE; Nelson, ER; McDonnell, DP

Published Date

  • November 2014

Published In

Volume / Issue

  • 90 /

Start / End Page

  • 30 - 38

PubMed ID

  • 25084324

Pubmed Central ID

  • PMC4192009

Electronic International Standard Serial Number (EISSN)

  • 1878-5867

Digital Object Identifier (DOI)

  • 10.1016/j.steroids.2014.07.013


  • eng

Conference Location

  • United States